Navigation Links
FDA's Lawrence Yu to Participate in Live Video Chat on Question-Based Review (QbR) for Generics on CPhI Pharma Evolution
Date:8/20/2013

NEW YORK, Aug. 20, 2013 /PRNewswire/ -- On Thursday, August 22, at 10:00 a.m. ET, FDA's Lawrence Yu, PhD, will take part in an hour-long video chat on CPhI Pharma Evolution, to discuss the QbR process and address pharma professionals' questions on the initiative and what it means for generic drug manufacturers.

The FDA's Question-Based Review process for generic drugs brings more modern principles from the FDA's cGMPs for the 21st century initiative into CMC evaluations for ANDAs. The process was developed to ensure that what is most critical to final product quality is prioritized in generic drug development, and brings more of the science-based approach found in NDA review to ANDAs. It also aims to have generic manufacturers demonstrate more effective and efficient manufacturing and scale-up approaches, and to integrate the fundamental principles of pharmaceutical QbD into their drug development programs.

Yu, who was instrumental in developing the QbD process, was formerly Director of Science in the FDA's Office of Generic Drugs, is now Acting Deputy Director of its Office of Pharmaceutical Science, and oversees the FDA's Office of New Drug Quality Assessment, Office of Generic Drug Quality Assessment, Office of Biotechnology Products, and Office of Testing and Research.

For more information and to participate in the live video chat, click here: http://www.pharmaevolution.com/video-stream.asp?section_id=3043&doc_id=560782

Contact 
Amy Averbook 
Sr. Marketing Director
UBM DeusM
(917) 743-2693  
averbook@deusm.com

About UBM DeusM
UBM DeusM (www.deusm.com) is an integrated marketing services company owned by UBM plc, targeting the fastest grow
'/>"/>

SOURCE CPhI Pharma Evolution
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lawrence Livermore engineering team makes breakthrough in solar energy research
2. ViroPharma to Participate in Two December Healthcare Investor Conferences
3. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
4. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
5. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
6. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
7. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
8. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
9. AVANIR Pharmaceuticals To participate in two conferences in March
10. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
11. ViroPharma To Participate In Two May Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, and Lee,s ... Code: 0950), a research-based biopharmaceutical company headquartered in ... operations in China , today announced ... WuXi,s Laboratory Testing Division (LTD) will be the exclusive ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, ... Knapp, Wis. The company has added a AS16 Sharples centrifuge to harvest products ... during bacterial or fungal fermentation process development. , The new centrifuge greatly ...
(Date:8/25/2015)... ... 2015 , ... One of the world’s foremost authorities on supply chain risk ... been on a mission for the past two weeks. She’s been scrambling to warn ... the two massive explosions that occurred on August 12 at the Ruihai International Logistics ...
(Date:8/25/2015)... Fla. , Aug. 25, 2015  InformedDNA, ... today that it has been awarded Certification in ... Assurance (NCQA). NCQA is a ... accredits and certifies a wide range of healthcare ... key areas of performance. "Our achievement ...
Breaking Biology Technology:WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3New centrifuge and fermentor expand product development capacity at Vets Plus 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4InformedDNA Achieves NCQA Utilization Management Certification 2
... PARIS, Sept. 7, 2011 Cellectis (Alternext: ... announced that its nuclease production capacity has ... costs. Industrialization of the nuclease manufacturing gives ... commercial subsidiary of Cellectis, the potential to ...
... and OXFORD, England, Sept. 7, 2011 CMC Biologics ... entered into a non-exclusive license agreement providing OBT with ... financial terms of which have not been disclosed, covers ... by OBT. CMC Biologics, CHEF1 cell line development platform ...
... Inc. (Nasdaq: RDEA ) announced today that it ... and Drug Administration (FDA) and successfully reached agreement on the ... plan: the overall size and design of the planned Phase ... proposed for NDA filing, manufacturing plans for both drug substance ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/10/2015)... 2015 The latest 364 page report ... of the global border security market . Visiongain ... in 2015. Now: Border security is hard to ... the business critical issue you need to know about - ... objective analysis of how this will impact your company and ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
UBC13 Antibody...
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... Antibody, Catalog #9251, 200 ul SAPK/JNK ... ul SAPK/JNK Cell Extracts, Catalog #9253, ... Antibody, Catalog #7074, 100 ul Anti-biotin ...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Biology Products: